Philips Joins Forces with AWS to Bring Philips HealthSuite Imaging PACS to the Cloud and Advance AI-enabled Tools In Support of Clinicians

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced the availability of Philips HealthSuite Imaging on Amazon Web Services (AWS). Additionally, Philips and AWS will build on their relationship, advancing AI in healthcare by applying Foundation Models using Amazon Bedrock to accelerate the development of cloud-based generative AI applications that will provide clinical decision support, help enable more accurate diagnoses, and automate administrative tasks.

The availability of Philips HealthSuite Imaging on AWS is a new addition to Philips’ broad capabilities in enterprise informatics, enabling improved image access speeds, reliability, and data orchestration for radiologists and clinicians across the entire imaging workflow – from diagnosis to therapy selection, treatment, and follow-up. Clinicians will be able to access the latest innovations from any location, and healthcare organizations can reduce costs previously invested in on-premises hardware or data centers to host their image management platform.

Philips can help clinicians manage growing workloads amidst staff shortages and speed time to diagnosis and treatment, enhancing patient outcomes. Philips HealthSuite Imaging will use Amazon HealthLake Imaging to increase scale, deliver fast time to first image, enable easy re-use of images for Machine Learning and research, and reduce medical imaging costs.

Philips will also use Amazon Bedrock as part of its efforts to develop generative AI applications to advance PACS image processing capabilities and simplify clinical workflows and voice recognition. Amazon Bedrock will enable Philips to develop Machine Learning-based applications quickly and reduce model development costs versus building Foundational Models (FMs) from scratch or running multiple task-specific model development efforts.

“With healthcare systems under increasing pressure, the focus of clinicians’ has shifted from technical specifications towards more efficient workflows that lead to accurate diagnoses – and that’s what we are delivering here,” said Shez Partovi, Chief Innovation & Strategy Officer and Business Leader Enterprise Informatics at Philips. “By shifting from on-premises to the cloud, we can leverage the security, reliability, and unmatched breadth and depth of AWS to support healthcare organizations in their mission to deliver high quality care while easing the burden on their staff.”

Swami Sivasubramanian vice president of database, analytics, and machine learning at AWS, said:

“Through democratizing access to generative AI and applying FMs to help support clinical decision-making, increase diagnostic accuracy, and automate administrative tasks, AWS will continue to support Philips as they uncover new ways to simplify radiologists’ workflow and reduce cognitive burden and clinician burnout.”

“Healthcare organizations are looking for ways to decrease operational costs, improve health data interoperability, and enable data-driven decision making for clinicians to improve access to quality patient-centered care,” said Swami Sivasubramanian, vice president of database, analytics, and machine learning at AWS. “Through democratizing access to generative AI and applying FMs to help support clinical decision-making, increase diagnostic accuracy, and automate administrative tasks, AWS will continue to support Philips as they uncover new ways to simplify radiologists’ workflow and reduce cognitive burden and clinician burnout.”

Philips and AWS provide migration expertise and planning services, total-cost-of-ownership analysis, and cybersecurity technical expertise to enable an easy migration from on-premises to cloud-based solutions for customers.

To learn more about Philips’ enterprise informatics portfolio, join Philips in person at HIMSS23 at booth #901 or visit Philips’ virtual informatics experience and follow @PhilipsLiveFrom for #HIMSS23 updates throughout the event.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”